Tianmei Niu
Tianmei Niu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Beibei Mao
School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250355, PR China
1 shared publication - Hong Wang
School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China
1 shared publication - Jiayu Zhang
School of Pharmacy, Binzhou Medical University, Yantai, China
1 shared publication - Jie Li
School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100029, China
1 shared publication - Jing Sun
College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
1 shared publication - Linlin Sun
College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
1 shared publication
Latest Publications
- Open Access
Chemical Components and Hypouricemic Activity Monitoring of Astragali radix-Huaier During Fermentation Processing Using High-Resolution Mass Spectrometry Combined with Untargeted Metabolomics
Recent evidence highlights the therapeutic potential of Astragali radix-Huaier fermentation products for hyperuricemia treatment, although the dynamics of the fermentation process remain poorly understood. This study employed high-resolution mass spectrometry and untargeted metabolomics for real-time monitoring of chemical components and hypouricemic activity throughout fermentation. The results revealed significant alterations in the chemical composition, with distinct sample separations observed on days 7, 14, 21, and 28. A total of 33 differential components were identified, including 20 flavonoids and 13 saponins, eight of which showed notable changes. Polysaccharides and saponins were found to correlate positively with the uric acid-lowering effect. On day 21, the levels of total polysaccharides and cycloastragenol-6-glucoside, a saponin derivative, peaked, coinciding with the highest hypouricemic activity of the Astragalus fungal fermentation products. This study provides the first evidence of dynamic changes in the chemical profile and pharmacological activity of Astragali radix-Huaier during fermentation, paving the way for optimizing fermentation processes and developing medicinal and dietary products based on Astragali radix.
Open AccessChemical Components and Hypouricemic Activity Monitoring of Astragali radix-Huaier During Fermentation Processing Using High-Resolution Mass Spectrometry Combined with Untargeted Metabolomics
Recent evidence highlights the therapeutic potential of Astragali radix-Huaier fermentation products for hyperuricemia treatment, although the dynamics of the fermentation process remain poorly understood. This study employed high-resolution mass spectrometry and untargeted metabolomics for real-time monitoring of chemical components and hypouricemic activity throughout fermentation. The results revealed significant alterations in the chemical composition, with distinct sample separations observed on days 7, 14, 21, and 28. A total of 33 differential components were identified, including 20 flavonoids and 13 saponins, eight of which showed notable changes. Polysaccharides and saponins were found to correlate positively with the uric acid-lowering effect. On day 21, the levels of total polysaccharides and cycloastragenol-6-glucoside, a saponin derivative, peaked, coinciding with the highest hypouricemic activity of the Astragalus fungal fermentation products. This study provides the first evidence of dynamic changes in the chemical profile and pharmacological activity of Astragali radix-Huaier during fermentation, paving the way for optimizing fermentation processes and developing medicinal and dietary products based on Astragali radix.
- Open Access
Molecular Insight into the Binding of Astilbin with Human Serum Albumin and Its Effect on Antioxidant Characteristics of Astilbin
Astilbin is a dihydroflavonol glycoside identified in many natural plants and functional food with promising biological activities which is used as an antioxidant in the pharmaceutical and food fields. This work investigated the interaction between astilbin and human serum albumin (HSA) and their effects on the antioxidant activity of astilbin by multi-spectroscopic and molecular modeling studies. The experimental results show that astilbin quenches the fluorescence emission of HSA through a static quenching mechanism. Astilbin and HSA prefer to bind at the Site Ⅰ position, which is mainly maintained by electrostatic force, hydrophobic and hydrogen bonding interactions. Multi-spectroscopic and MD results indicate that the secondary structure of HSA could be changed because of the interaction of astilbin with HSA. DPPH radical scavenging assay shows that the presence of HSA reduces the antioxidant capacity of astilbin. The explication of astilbin–HSA binding mechanism will provide insights into clinical use and resource development of astilbin in food and pharmaceutical industries.
Open AccessMolecular Insight into the Binding of Astilbin with Human Serum Albumin and Its Effect on Antioxidant Characteristics of Astilbin
Astilbin is a dihydroflavonol glycoside identified in many natural plants and functional food with promising biological activities which is used as an antioxidant in the pharmaceutical and food fields. This work investigated the interaction between astilbin and human serum albumin (HSA) and their effects on the antioxidant activity of astilbin by multi-spectroscopic and molecular modeling studies. The experimental results show that astilbin quenches the fluorescence emission of HSA through a static quenching mechanism. Astilbin and HSA prefer to bind at the Site Ⅰ position, which is mainly maintained by electrostatic force, hydrophobic and hydrogen bonding interactions. Multi-spectroscopic and MD results indicate that the secondary structure of HSA could be changed because of the interaction of astilbin with HSA. DPPH radical scavenging assay shows that the presence of HSA reduces the antioxidant capacity of astilbin. The explication of astilbin–HSA binding mechanism will provide insights into clinical use and resource development of astilbin in food and pharmaceutical industries.